Aktieanalys

Cyxone: Priority on Rheumatoid Arthritis in Focused Strategy - Redeye

{newsItem.title}

Redeye Publicerad: 29 Apr 2022 14:08

Redeye comments on Cyxone’s recently announced strategy that focuses on lead project Rabeximod in RA.

Länk till analysen i sin helhet: https://www.redeye.se/research/839972/cyxone-priority-on-rheumatoid-arthritis-in-focused-strategy?utm_source=finwire&utm_medium=RSS

Nyheter om Cyxone

Läses av andra just nu

Om aktien Cyxone

Senaste nytt